Lung Cancer
AMG 757: 20240178 A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Details
ClinicalTrials.gov ID:
NCT07005128
Diagnosis Type:
NA
USOR Number:
- Address
,
P: